Literature DB >> 32691837

Sepsis in Immunocompromised Patients Without Human Immunodeficiency Virus.

Randy J McCreery1, Diana F Florescu1,2, Andre C Kalil1.   

Abstract

Sepsis remains among the most common complications from infectious diseases worldwide. The morbidity and mortality rates associated with sepsis range from 20% to 50%. The advances in care for patients with an immunocompromised status have been remarkable over the last 2 decades, but sepsis continues to be a major cause of death in this population Immunocompromised patients who are recipients of a solid organ or hematopoietic stem cell transplant are living longer with a better quality of life. However, some of these patients need lifelong treatment with immunosuppressive medications to maintain their transplant status. A consequence of the need for this permanent immunosuppression is the high risk of opportunistic, community, and hospital-acquired infections, all of which can lead to sepsis. In addition, the detection of serious infections may be more challenging owing to patients' lower ability to mount the clinical symptoms that usually accompany sepsis. This article provides an update on the current knowledge of sepsis in immunocompromised patients without human immunodeficiency virus. It reviews the most pertinent causes of sepsis in this population, and addresses the specific diagnostic and therapeutic challenges in neutropenia and solid organ and hematopoietic stem cell transplantation.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  immunocompromised; sepsis; solid organ transplant; stem cell transplant

Year:  2020        PMID: 32691837     DOI: 10.1093/infdis/jiaa320

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Impact of Sepsis on High-Density Lipoprotein Metabolism.

Authors:  Alexander C Reisinger; Max Schuller; Harald Sourij; Julia T Stadler; Gerald Hackl; Philipp Eller; Gunther Marsche
Journal:  Front Cell Dev Biol       Date:  2022-01-05

2.  A Nomogram Based on Comorbidities and Infection Location to Predict 30 Days Mortality of Immunocompromised Patients in ICU: A Retrospective Cohort Study.

Authors:  Xuequn Guo; Donghao Guo
Journal:  Int J Gen Med       Date:  2021-12-24

3.  Prospective validation of a transcriptomic severity classifier among patients with suspected acute infection and sepsis in the emergency department.

Authors:  Noa Galtung; Eva Diehl-Wiesenecker; Dana Lehmann; Natallia Markmann; Wilma H Bergström; James Wacker; Oliver Liesenfeld; Michael Mayhew; Ljubomir Buturovic; Roland Luethy; Timothy E Sweeney; Rudolf Tauber; Kai Kappert; Rajan Somasundaram; Wolfgang Bauer
Journal:  Eur J Emerg Med       Date:  2022-04-21       Impact factor: 4.106

4.  Clinical Value of Metagenomic Next-Generation Sequencing in Immunocompromised Patients with Sepsis.

Authors:  Zheng Cheng; Feng Yu
Journal:  Med Sci Monit       Date:  2022-08-12

5.  Immune response to third SARS-CoV-2 vaccination in seronegative kidney transplant recipients: Possible improvement by mycophenolate mofetil reduction.

Authors:  Marta Kantauskaite; Lisa Müller; Jonas Hillebrandt; Joshua Lamberti; Svenja Fischer; Thilo Kolb; Katrin Ivens; Michael Koch; Marcel Andree; Nadine Lübke; Michael Schmitz; Tom Luedde; Hans Martin Orth; Torsten Feldt; Heiner Schaal; Ortwin Adams; Claudia Schmidt; Margarethe Kittel; Eva Königshausen; Lars C Rump; Jörg Timm; Johannes Stegbauer
Journal:  Clin Transplant       Date:  2022-08-23       Impact factor: 3.456

Review 6.  Bacterial and Viral Infection and Sepsis in Kidney Transplanted Patients.

Authors:  Alberto Mella; Filippo Mariano; Caterina Dolla; Ester Gallo; Ana Maria Manzione; Maria Cristina Di Vico; Rossana Cavallo; Francesco Giuseppe De Rosa; Cristina Costa; Luigi Biancone
Journal:  Biomedicines       Date:  2022-03-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.